COVID-19 among heart transplant recipients in Germany: a multicenter survey / Rasmus Rivinius, Ziya Kaya, René Schramm, Udo Boeken, Zdenek Provaznik, Christian Heim, Christoph Knosalla, Felix Schoenrath, Andreas Rieth, Michael Berchtold-Herz, Markus J. Barten, Dominic Rauschning, Victoria T. Mücke, Stephan Heyl, Rudin Pistulli, Carola Grinninger, Christian Hagl, Jan Gummert, Gregor Warnecke, P. Christian Schulze, Hugo A. Katus, Michael M. Kreusser, Philip Raake
Abstract: Aims<br>Heart transplantation may represent a particular risk factor for severe coronavirus infectious disease 2019 (COVID-19) due to chronic immunosuppression and frequent comorbidities. We conducted a nation-wide survey of all heart transplant centers in Germany presenting the clinical characteristics of heart transplant recipients with COVID-19 during the first months of the pandemic in Germany.<br><br>Methods and results<br>A multicenter survey of all heart transplant centers in Germany evaluating the current status of COVID-19 among adult heart transplant recipients was performed. A total of 21 heart transplant patients with COVID-19 was reported to the transplant centers during the first months of the pandemic in Germany. Mean patient age was 58.6 ± 12.3 years and 81.0% were male. Comorbidities included arterial hypertension (71.4%), dyslipidemia (71.4%), diabetes mellitus (33.3%), chronic kidney failure requiring dialysis (28.6%) and chronic-obstructive lung disease/asthma (19.0%). Most patients received an immunosuppressive drug regimen consisting of a calcineurin inhibitor (71.4%), mycophenolate mofetil (85.7%) and steroids (71.4%). Eight of 21 patients (38.1%) displayed a severe course needing invasive mechanical ventilation. Those patients showed a high mortality (87.5%) which was associated with right ventricular dysfunction (62.5% vs. 7.7%; p = 0.014), arrhythmias (50.0% vs. none; p = 0.012), and thromboembolic events (50.0% vs. none; p = 0.012). Elevated high-sensitivity cardiac troponin T- and N-terminal prohormone of brain natriuretic peptide were significantly associated with the severe form of COVID-19 (p = 0.017 and p < 0.001, respectively).<br><br>Conclusion<br>Severe course of COVID-19 was frequent in heart transplanted patients. High mortality was associated with right ventricular dysfunction, arrhythmias, thromboembolic events, and markedly elevated cardiac biomarkers.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
Berlin: Springer ; 2020 Freiburg: Albert-Ludwigs-Universität Freiburg ; 2020 |
| Enthalten in: |
Clinical research in cardiology - 109 (2020), 1531–1539 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rivinius, Rasmus [VerfasserIn] |
|---|
| Links: |
nbn-resolving.de [kostenfrei] |
|---|
| Umfang: |
1 Online-Ressource (9 Seiten) |
|---|
| doi: |
10.1007/s00392-020-01722-w |
|---|---|
| Weitere IDs: |
urn:nbn:de:bsz:25-freidok-1696054 FRUB-opus-169605 |
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1746333839 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1746333839 | ||
| 003 | DE-627 | ||
| 005 | 20230426174243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210201s2020 gw |||||o 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:bsz:25-freidok-1696054 |2 urn | |
| 024 | 7 | |a 10.1007/s00392-020-01722-w |2 doi | |
| 024 | 8 | |a FRUB-opus-169605 |q Opus Nr. | |
| 035 | |a (DE-627)1746333839 | ||
| 035 | |a (DE-599)KXP1746333839 | ||
| 035 | |a (OCoLC)1235759862 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-DE-BW | ||
| 082 | 0 | |a 616.1 |q DE-101 | |
| 082 | 0 | 4 | |a 610 |q DE-101 |
| 100 | 1 | |a Rivinius, Rasmus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 among heart transplant recipients in Germany: a multicenter survey |c Rasmus Rivinius, Ziya Kaya, René Schramm, Udo Boeken, Zdenek Provaznik, Christian Heim, Christoph Knosalla, Felix Schoenrath, Andreas Rieth, Michael Berchtold-Herz, Markus J. Barten, Dominic Rauschning, Victoria T. Mücke, Stephan Heyl, Rudin Pistulli, Carola Grinninger, Christian Hagl, Jan Gummert, Gregor Warnecke, P. Christian Schulze, Hugo A. Katus, Michael M. Kreusser, Philip Raake |
| 264 | 1 | |a Berlin |b Springer |c 2020 | |
| 264 | 2 | |a Freiburg |b Albert-Ludwigs-Universität Freiburg |c 2020 | |
| 300 | |a 1 Online-Ressource (9 Seiten) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract: Aims<br>Heart transplantation may represent a particular risk factor for severe coronavirus infectious disease 2019 (COVID-19) due to chronic immunosuppression and frequent comorbidities. We conducted a nation-wide survey of all heart transplant centers in Germany presenting the clinical characteristics of heart transplant recipients with COVID-19 during the first months of the pandemic in Germany.<br><br>Methods and results<br>A multicenter survey of all heart transplant centers in Germany evaluating the current status of COVID-19 among adult heart transplant recipients was performed. A total of 21 heart transplant patients with COVID-19 was reported to the transplant centers during the first months of the pandemic in Germany. Mean patient age was 58.6 ± 12.3 years and 81.0% were male. Comorbidities included arterial hypertension (71.4%), dyslipidemia (71.4%), diabetes mellitus (33.3%), chronic kidney failure requiring dialysis (28.6%) and chronic-obstructive lung disease/asthma (19.0%). Most patients received an immunosuppressive drug regimen consisting of a calcineurin inhibitor (71.4%), mycophenolate mofetil (85.7%) and steroids (71.4%). Eight of 21 patients (38.1%) displayed a severe course needing invasive mechanical ventilation. Those patients showed a high mortality (87.5%) which was associated with right ventricular dysfunction (62.5% vs. 7.7%; p = 0.014), arrhythmias (50.0% vs. none; p = 0.012), and thromboembolic events (50.0% vs. none; p = 0.012). Elevated high-sensitivity cardiac troponin T- and N-terminal prohormone of brain natriuretic peptide were significantly associated with the severe form of COVID-19 (p = 0.017 and p < 0.001, respectively).<br><br>Conclusion<br>Severe course of COVID-19 was frequent in heart transplanted patients. High mortality was associated with right ventricular dysfunction, arrhythmias, thromboembolic events, and markedly elevated cardiac biomarkers | ||
| 700 | 1 | |a Kaya, Ziya |d 1971- |e verfasserin |0 (DE-588)120790319 |0 (DE-627)704990016 |0 (DE-576)292386672 |4 aut | |
| 700 | 1 | |a Schramm, René |e verfasserin |4 aut | |
| 700 | 1 | |a Boeken, Udo |d 1967- |e verfasserin |0 (DE-588)172602645 |0 (DE-627)697537404 |0 (DE-576)13346203X |4 aut | |
| 700 | 1 | |a Provaznik, Zdenek |e verfasserin |4 aut | |
| 700 | 1 | |a Heim, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Knosalla, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Schönrath, Felix |d 1980- |e verfasserin |0 (DE-588)130175544 |0 (DE-627)707420644 |0 (DE-576)190115696 |4 aut | |
| 700 | 1 | |a Rieth, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Berchtold-Herz, Michael |e verfasserin |0 (DE-588)1136800158 |0 (DE-627)893590304 |0 (DE-576)490847676 |4 aut | |
| 700 | 1 | |a Barten, Markus J. |e verfasserin |4 aut | |
| 700 | 1 | |a Rauschning, Dominic |e verfasserin |4 aut | |
| 700 | 1 | |a Mücke, Victoria T. |e verfasserin |4 aut | |
| 700 | 1 | |a Heyl, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Pistulli, Rudin |e verfasserin |4 aut | |
| 700 | 1 | |a Grinninger, Carola |e verfasserin |4 aut | |
| 700 | 1 | |a Hagl, Christian Matthias |d 1967- |e verfasserin |0 (DE-588)115596879 |0 (DE-627)077352270 |0 (DE-576)289969514 |4 aut | |
| 700 | 1 | |a Gummert, Jan |d 1963- |e verfasserin |0 (DE-588)111735203 |0 (DE-627)691126151 |0 (DE-576)348540310 |4 aut | |
| 700 | 1 | |a Warnecke, Gregor |d 1974- |e verfasserin |0 (DE-588)125001517 |0 (DE-627)370699629 |0 (DE-576)294612823 |4 aut | |
| 700 | 1 | |a Schulze, Paul Christian |d 1972- |e verfasserin |0 (DE-588)121635244 |0 (DE-627)705591433 |0 (DE-576)181718200 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e verfasserin |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 700 | 1 | |a Kreusser, Michael M. |e verfasserin |4 aut | |
| 700 | 1 | |a Raake, Philip |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Sonderdruck aus |t Clinical research in cardiology |g 109 (2020), 1531–1539 |x 1861-0692 |
| 856 | 4 | 0 | |u https://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-1696054 |q application/pdf |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00392-020-01722-w |v 2022-02-07 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bsz:25-freidok-1696054 |v 2022-02-07 |x Resolving-System |
| 856 | 4 | 0 | |u https://d-nb.info/1223849015/34 |v 2022-02-07 |x Langzeitarchivierung Nationalbibliothek |
| 856 | 4 | 0 | |u https://freidok.uni-freiburg.de/data/169605 |q application/pdf |v 2022-02-07 |x Verlag |z kostenfrei |
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 935 | |c so | ||
| 951 | |a BO | ||
| 953 | |2 045F |a 616.1 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3846318388 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |k Elektronischer Volltext - Zugang über WWW |y l01 |z 01-02-21 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 3850987604 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 10-02-21 | ||
| 981 | |2 2003 |1 01 |x DE-25 |r http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-1696054 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1007/s00392-020-01722-w | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-1696054 | ||
| 982 | |2 2003 |1 01 |x DE-25 |8 00 |s s |a Cardiology and Cardiovascular Medicine | ||
| 982 | |2 2003 |1 01 |x DE-25 |8 01 |s s |a General Medicine | ||